



POSTER PRESENTATION

Open Access

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients

P Quartier^{1*}, N Ruperto², N Wulffraat², H Brunner³, R Brik², L Mccann², H Foster², M Frosch², V Gerloni², L Harel², C Len², K Houghton³, R Joos², K Abrams⁴, K Lheritier⁵, S Kessabi⁵, A Martini², D Lovell³

From 20th Pediatric Rheumatology European Society (PReS) Congress Ljubljana, Slovenia. 25-29 September 2013

Introduction

Canakinumab (CAN), a selective, fully human, anti-interleukin-1 β monoclonal antibody, has been shown to be efficacious in SJIA patients (pts) in 2 phase 3 trials: Trial 1 (4-wk, randomized placebo [PBO]-controlled) and Trial 2 (open-label CAN treatment [Part 1] followed by a randomized PBO-controlled withdrawal phase [Part 2]). In Trial 1, statistically significantly more CAN than PBO group pts achieved an adapted pediatric ACR 30 response and in Trial 2, CAN allowed successful reduction/discontinuation of steroids and significantly reduced risk of flare. Safety profile of CAN was in line with expectations for a biologic agent in active SJIA. The persistent disabling features of SJIA and chronic pain can have a negative impact on health-related quality of life (hrqol). These outcomes were evaluated in the CAN phase 3 program.

Objectives

To report pt-reported functional ability and hrqol outcomes from the CAN phase 3 program.

Methods

The phase 3 analysis included 84 pts (CAN, 43; PBO, 41) in Trial 1 and 177 pts in Trial 2 (71 from Trial 1 entered) in Part 1, and 100 rolled into Part 2 (CAN, 50; PBO, 50). Pt-reported assessments included functional ability (as measured by the Childhood Health Assessment Questionnaire [CHAQ[®]]), pain (measured on a visual analog scale [VAS] of 0-100 mm as part of the CHAQ[®]), and physical (phs) and psychosocial (pss) health status in 5-18 year old pts., according to the Child Health Questionnaire-Parent Form (CHQ-PF50).

Results

In Trial 1, CAN treatment was associated with a significant improvement in CHAQ disability score (estimated difference [ED] of -0.69 over time vs PBO in the least square mean [LSM] change from baseline [BL] [p = 0.0002]), which was ~3.6 \times the minimal clinically important difference of -0.19. The LSM in overall pain intensity were significantly lower (both p < 0.0001) in the CAN group vs

Table 1 Patient- or Parent-reported functional ability and hrqol parameters in Trial 2

Outcome measure, mean (SD)	Baseline CAN, N = 177	End of Part 1 CAN, N = 177	End of Part 2 CAN, N = 50	End of Part 2 PBO, N = 50
CHAQ disability score	1.7 (0.8)	0.74 (0.9)	0.5 (0.9)	0.6 (0.8)
Pain (VAS, 0-100 mm)	66.6 (23.3)	20.2 (25.8)	13.6 (26.9)	17.0 (24.2)
CHQ-PF50 phs score	16.1 (14.3)	37.7 (17.2)	43.6 (17.4)	39.0 (18.1)
CHQ-PF50 pss score	41.6 (11.1)	50.7 (11.1)	53.6 (11.3)	52.7 (9.8)

Results are based on patients with both baseline and post-baseline values. N18 years old.

¹Necker-Enfant Malades Hospital, Paris, France

Full list of author information is available at the end of the article

PBO both at Day 15 (ED, -46.42) and Day 29 (ED, -41.86). CHQ-PF50 phs and pss scores also showed significant improvements over time (ED CAN vs PBO in LSM change from BL, 12.07 and 7.28; $p < 0.005$ for both). Improvements in CHAQ disability, CHQ-PF50 phs and pss, and VAS pain scores were also observed in Trial 2 (Table 1).

Conclusion

Treatment with CAN demonstrated rapid, marked and continued improvement in patient-reported functional ability and hrqol of SJIA patients.

Disclosure of interest

P. Quartier Grant/Research Support from: Abbvie, Chugai-Roche, Novartis, Pfizer, Consultant for: Abbvie, BMS, Chugai-Roche, Novartis, Pfizer, Servier, Sweedish Orphan Biovitrum, Speakers Bureau: Chugai-Roche, Novartis, Pfizer, N. Ruperto Grant/Research Support from: To Gaslini Hospital: Abbott, Astrazeneca, BMS, Centocor Research & Development, Eli Lilly and Company, "Francesco Angelini", Glaxo Smith & Kline, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences gmbh, Xoma, Wyeth Pharmaceuticals Inc., Speakers Bureau: Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Roche, Wyeth/Pfizer, N. Wulffraat Consultant for: Novartis, Pfizer, Roche, H. Brunner Consultant for: Novartis, Genentech, Medimmune, EMD Serono, AMS, Pfizer, UCB, Janssen, Speakers Bureau: Genentech, R. Brik Grant/Research Support from: Novartis, Consultant for: Novartis, L. Mccann: None declared., H. Foster Grant/Research Support from: Pfizer, biomarin, Speakers Bureau: Pfizer, M. Frosch: None declared., V. Gerloni: None declared., L. Harel: None declared., C. Len: None declared., K. Houghton: None declared., R. Joos: None declared., K. Abrams Shareholder of: Novartis, Employee of: Novartis, K. Lheritier Shareholder of: Novartis, Employee of: Novartis, S. Kessabi Employee of: Novartis, A. Martini Grant/Research Support from: Abbott, Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Ely Lilly and Company, "Francesco Angelini", Glaxo Smith & Kline, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Bisciencs, gmbh, Xoma, Wyeth Pharmaceuticals Inc.(Consulting fee). The GASLINI hospital which is a public hospital where I work as full time employee has received contributions to support the research activities of the network of PRINTO (<http://www.printo.it>), Consultant for: Abbott, Astrazeneca, Bristol Myers and Squibb, Janssen Biologics B.V., Ely Lilly and Company, Francesco A, Glaxo Smith & Klime, Italfarmaco, Novartis, Pfizer Inc., Roche, Sanofi Aventis, Schwarz Biosciences gmbh, Xoma, Wyeth Pharmaceuticals, Speakers Bureau: Astellas, Astrazeneca, Bristol Myers and Squibb, Glaxo Smith & Kline, Italfarmaco, medimmune, Novartis, D. Lovell Grant/Research Support from: NIH,

Consultant for: Astra-Zeneca, Centocor, Janssen, Wyeth, Amgen, Bristol-Meyers Squibb, Abbott, Pfizer, Regeneron, Hoffman La-Roche, Novartis, Genentech, Speakers Bureau: Genentech, Roche.

Authors' details

¹Necker-Enfant Malades Hospital, Paris, France. ²PRINTO-Istituto Gaslini, Genova, Italy. ³PRCSG, Cincinnati, OH, USA. ⁴Novartis Pharmaceuticals Corporation, EH, NJ, USA. ⁵Novartis Pharma AG, Basel, Switzerland.

Published: 5 December 2013

doi:10.1186/1546-0096-11-S2-P170

Cite this article as: Quartier et al.: PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients. *Pediatric Rheumatology* 2013 **11**(Suppl 2):P170.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

